Cellusion

Developer of iPS cell-based regenerative technology for bullous keratopathy

placeMinato City, Tokyo, Japan calendar_todayFounded 2015 groups15 employees language cellusion.jp

Innovation

8 patent families — focus: Human necessities, Chemistry & metallurgy; filing pace accelerating. Cited 76 times.

YearFilings
20233
20243
20256

Investor mix

15 investors on record; lead investors include DBJ Capital, Keio Innovation Initiative, Gemseki, SMBC Venture Capital.

Investor typeCountShare
Venture capital747%
Private equity17%
Bank & private debt17%
Other / undisclosed640%
Coming soon